2025 Global Anti-Retroviral Drugs Revenue Opportunities Report
Description
The 2025 Global Anti-Retroviral Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the global anti-retroviral drugs market are Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co. Gilead is the market leader, holding about 64% of its revenue from HIV therapeutics and dominating with high-revenue drugs such as Biktarvy, which generated roughly $12 billion worldwide in 2023. Gilead also innovates with long-acting formulations like Yeztugo (lenacapavir), the first FDA-approved twice-yearly injectable for HIV prevention. ViiV Healthcare, a consortium of GlaxoSmithKline, Pfizer, and Shionogi, focuses on injectable therapies like cabotegravir and maintains extensive licensing for access in low- and middle-income countries. Janssen extends its HIV drug portfolio by researching integrase inhibitors addressing comorbidities, and Merck collaborates on once-weekly oral regimens and technology platforms to diversify treatment options.
These firms strategically advance HIV treatment through continuous innovation, pipeline expansion, and global licensing collaborations to broaden drug access. Gilead's acquisition of innovative biotech assets, such as the HTI vaccine from AELIX Therapeutics, highlights its commitment to developing therapeutic vaccines aiming for a functional cure. ViiV works closely with generic manufacturers like Aurobindo and Cipla to enhance drug availability in resource-limited settings, while Janssen and Merck invest in lifecycle management to address evolving patient needs including aging populations and drug resistance. Their leadership drives a market valued at over $31 billion in 2025, with growth fueled by long-acting injectable therapies and expanding HIV prevalence worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the global anti-retroviral drugs market are Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co. Gilead is the market leader, holding about 64% of its revenue from HIV therapeutics and dominating with high-revenue drugs such as Biktarvy, which generated roughly $12 billion worldwide in 2023. Gilead also innovates with long-acting formulations like Yeztugo (lenacapavir), the first FDA-approved twice-yearly injectable for HIV prevention. ViiV Healthcare, a consortium of GlaxoSmithKline, Pfizer, and Shionogi, focuses on injectable therapies like cabotegravir and maintains extensive licensing for access in low- and middle-income countries. Janssen extends its HIV drug portfolio by researching integrase inhibitors addressing comorbidities, and Merck collaborates on once-weekly oral regimens and technology platforms to diversify treatment options.
These firms strategically advance HIV treatment through continuous innovation, pipeline expansion, and global licensing collaborations to broaden drug access. Gilead's acquisition of innovative biotech assets, such as the HTI vaccine from AELIX Therapeutics, highlights its commitment to developing therapeutic vaccines aiming for a functional cure. ViiV works closely with generic manufacturers like Aurobindo and Cipla to enhance drug availability in resource-limited settings, while Janssen and Merck invest in lifecycle management to address evolving patient needs including aging populations and drug resistance. Their leadership drives a market valued at over $31 billion in 2025, with growth fueled by long-acting injectable therapies and expanding HIV prevalence worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
